Antagonists of interleukin-15
AssigneeImmunex Corporation
InventorsKenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
Life of this patent
Estimating the term…
Abstract
Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or γ-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
Claims38
An antagonist of interleukin-15 (IL-15) activity comprising IL-15 or a mutein thereof, conjugated with a chemical group that sterically interferes with the ability of IL-15 to transduce a signal through the IL-15 receptor complex, wherein said antagonist is capable of binding to said IL-15 receptor complex.
An antagonist of interleukin-15 (IL-15) activity comprising native IL-15 comprising the sequence of amino acids 49–162 of SEQ ID NO:
- 2 conjugated with a chemical group that sterically interferes with the ability of IL-15 to transduce a signal through the IL-15 receptor complex, wherein said antagonist is capable of binding to said IL-15 receptor complex.
An antagonist of interleukin-15 (IL-15) activity comprising a mutein corresponding to amino acids 49–162 of SEQ ID:
- 2, wherein either or both of Asp56 or Gln156 are substituted with serine or cysteine, conjugated with a chemical group that sterically interferes with the ability of IL-15 to transduce a signal through the IL-15 receptor complex.
Dependencies are inferred from the claim text.